Note 7 - Research and Development Tax Rebate Receivable	3 Months Ended
Mar. 31, 2023
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 7: RESEARCH AND DEVELOPMENT REBATE RECEIVABLE On May 23, 2017, the Company formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities, including some of the Company's clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For entities with over 80% of revenue from passive sources, the rate increases to $0.485 per dollar. The Australian R&D tax incentive program is a self-assessment process, and as such, the Australian Government has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, and as a result of the review and failure of a related appeal, a qualified program and related expenditures could be disqualified, and the respective R&D rebates of $2,028 collected could be recalled with penalties and interest. The Company uses the grant accounting model by analogy to International Accounting Standards (IAS) 20 to account for the cash rebates received from the Australian government. During the three months ended March 31, 2023 and 2022, the Company incurred qualified R&D expenses in Australia of $52 and $354, respectively. There were no collections of R&D cash rebates during the three months ended March 31, 2023. The Company collected R&D cash rebates of $563, during the three months ended March 31, 2022. At March 31, 2023 and December 31, 2022 the Company had total R&D rebate receivables of $738 and $743, respectively. The Company records the R&D rebate credit in the period when it incurs the associated R&D cost. As such, the rebate reduced the Research and development expense line item in the Condensed Consolidated Statements of Operations by $15 and $140 for the three months ended March 31, 2023 and, 2022, respectively.

Note 7 - Research and Development Tax Rebate Receivable

3 Months Ended

Mar. 31, 2023

Research and Development Tax Rebate Receivable [Text Block]

NOTE 7: RESEARCH AND DEVELOPMENT REBATE RECEIVABLE

On May 23, 2017, the Company formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform R&D activities, including some of the Company's clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For entities with over 80% of revenue from passive sources, the rate increases to $0.485 per dollar. The Australian R&D tax incentive program is a self-assessment process, and as such, the Australian Government has the right to review the Company’s qualifying programs and related expenditures for a period of four years. If such a review were to occur, and as a result of the review and failure of a related appeal, a qualified program and related expenditures could be disqualified, and the respective R&D rebates of $2,028 collected could be recalled with penalties and interest. The Company uses the grant accounting model by analogy to International Accounting Standards (IAS) 20 to account for the cash rebates received from the Australian government.

During the three months ended March 31, 2023 and 2022, the Company incurred qualified R&D expenses in Australia of $52 and $354, respectively. There were no collections of R&D cash rebates during the three months ended March 31, 2023. The Company collected R&D cash rebates of $563, during the three months ended March 31, 2022. At March 31, 2023 and December 31, 2022 the Company had total R&D rebate receivables of $738 and $743, respectively. The Company records the R&D rebate credit in the period when it incurs the associated R&D cost. As such, the rebate reduced the Research and development expense line item in the Condensed Consolidated Statements of Operations by $15 and $140 for the three months ended March 31, 2023 and, 2022, respectively.